EMA Unveils New Data in Mid-year Report
During the first six months of 2014, the number of scientific advice and protocol assistance requests for human medicines received by the EMA increased by 16%
During the first six months of 2014, the number of scientific advice and protocol assistance requests for human medicines received by the European Medicines Agency (EMA) increased by 16% compared with the same period in 2013, according to the agency’s mid-year report presented to the Management Board on 2 October 2014.
Among the other highlights in the report are:
- The number of orphan designation applications was 138, a 30% increase over results in the first six months 2013. There was an 8% increase in pediatric procedure applications.
- EMA received 43 initial evaluation applications between January and June 2014, an increase of 19% compared with the same period of last year. This rise was mostly due to more generics applications received. The annual forecast for initial applications has been revised upwards from 88 to 118.
- New orphan medicinal product applications saw an increase to 9 applications (from 5 in 2013) in the first six months of 2014, thus returning to the level of applications in 2011-2012. The number of new non-orphan medicinal product applications received by the end of June 2014 fell slightly, compared to the same period of 2013 (20 versus 24).
- Biological medicinal product applications remained at the same low level as in 2013, as was also the case for hybrid and abridged applications.
For a full copy of the mid-year report, click here. (PDF)
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
